Bio-Path Holdings, Inc. (BPTH) Announces Major Corporate Developments

Key Highlights

• Domestication to Wyoming: Bio-Path Holdings, Inc. has officially completed its domestication from Delaware to Wyoming effective March 5, 2026. This move was approved by the Secretary of State of Wyoming, and all requisite paperwork has been stamped and filed.
• Amendment to Articles of Incorporation: The company has created a new class of Series S Preferred Stock, authorizing fifty-one (51) shares. Each Series S Preferred share is convertible into one common share and carries a significant 1% of the diluted voting power of the company. This is a material change in the capital structure and could influence future governance and voting outcomes.
• Emerging Growth Company Status: Bio-Path Holdings is not an emerging growth company, as indicated by the relevant check box. This means certain scaled disclosure and regulatory benefits are not applicable to BPTH.
• Appointment of Scientific Advisory Board: Effective February 10, 2026, Bio-Path has announced the appointment of two renowned experts to its newly formed Scientific Advisory Board:
  • Dr. Wendy M. Charles, PhD, MS, CIP, CCRP: Assistant Professor of Health Informatics at the University of Denver, Editor-in-Chief of Frontiers in Blockchain: Blockchain for Science journal section. Dr. Charles brings deep expertise in regulatory strategy, data governance, and technology-enabled research innovation, and has held executive roles in pharmaceutical and compliance sectors.
  • Michael Hickey: Currently Vice President of Clinical Operations at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), with prior roles at Amgen and Biomarin, as well as consulting experience in biotech and pharma operations. Mr. Hickey holds an MBA and a BSc in Exercise Physiology, and brings operational expertise in Hematology, Oncology, Clinical Monitoring, and Biotech.

  Both have signed three-year contracts to join the Scientific Advisory Board, marking a strategic enhancement of Bio-Path’s clinical and regulatory leadership.

• Corporate Headquarters Relocation: The principal executive office address has changed to 625 Stanwix St. #2407, Pittsburgh, PA 15222, with telephone number (630) 708-0750. This is a notable shift from the prior Texas address.
• Security Details: The company’s common stock (par value \$0.001) is now trading on OTC Pink under the symbol BPTH.
• Signature: The report is signed by Vikram Grover, Chief Executive Officer, Chief Financial Officer, and Director.

Potential Price-Sensitive Developments for Shareholders

• Domestication to Wyoming: This legal shift may affect the company’s regulatory environment, taxes, and governance structure. Wyoming is often considered more business-friendly, which could benefit BPTH’s operations and shareholder value.
• Creation of Series S Preferred Stock: The introduction of a new class of preferred shares, each representing a significant voting power, could alter control dynamics within the company. Investors should note the potential for these preferred shares to impact major corporate decisions, especially as they are convertible into common shares.
• Scientific Advisory Board Appointments: The strategic addition of Dr. Charles and Mr. Hickey brings considerable expertise in clinical operations, informatics, and regulatory compliance. Their backgrounds may improve Bio-Path’s prospects for drug development and innovation, possibly enhancing investor confidence and share price valuation.
• Relocation of Headquarters: Moving to Pittsburgh, PA, may be part of a broader strategic shift, possibly reflecting closer proximity to clinical research resources or other business advantages.
• Trading Status: BPTH is now trading on OTC Pink. Investors should be aware that this may affect liquidity, visibility, and regulatory oversight compared to previous exchange listings.

Additional Details for Investors

• The company’s fiscal year ends December 31.
• IRS Employer Identification Number: 87-0652870.
• Commission File Number: 001-36333.
• Former company names include Bio-Path Holdings Inc (name change in 2008) and Ogden Golf Co Corp (name change in 2001).
• Major exhibits attached to the filing:
  • Domestication to Wyoming paperwork (Exhibit 10.1).
  • Amendment for Series S Preferred Stock creation (Exhibit 10.2).
  • Cover Page Interactive Data File (Exhibit 104).

Conclusion

Bio-Path Holdings, Inc. has announced several material developments that could impact shareholders and the company’s future trajectory. The move to Wyoming, the creation of Series S Preferred Stock (with unique voting rights), and the appointment of two distinguished experts to its Scientific Advisory Board are all potentially price-sensitive events. Investors should monitor these developments closely, as they may influence corporate governance, strategic direction, and the company’s ability to advance its oncology therapeutics pipeline.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please conduct your own due diligence or consult a professional advisor before making any investment decisions regarding Bio-Path Holdings, Inc. The information herein is based on publicly available filings and may be subject to change without notice.

View BIO-PATH HOLDINGS, INC. Historical chart here